Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candidate for metabolic diseases. However， the disadvantages of FGF21 as a clinically useful medicine include its short plasma half-life and poor drug-like properties. Here， we have explored the effects of PsTag600-FGF21， an engineered long-acting FGF21 fusion protein， in mice with NASH and describe some of the underlying mechanisms.
Non-alcoholic steatohepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease and is a serious public health problem around the world. There are currently no approved treatments for NASH. FGF21 has recently emerged as a promising drug candidate for metabolic diseases. However， the disadvantages of FGF21 as a clinically useful medicine include its short plasma half-life and poor drug-like properties. Here， we have explored the effects of PsTag600-FGF21， an engineered long-acting FGF21 fusion protein， in mice with NASH and describe some of the underlying mechanisms.
